A clinical-stage psychedelics company developing therapeutics for addiction, PTSD and depression
Solvonis Therapeutics plc (LSE: SVNS) is building an alcohol use disorder franchise across the UK, Europe and the U.S., and a de novo engine of proprietary new medicines.
A clinical-stage psychedelics company with two complementary development strategies
Scientific leadership: Professor David Nutt, Chief Scientific Officer, and Edmond J Safra Professor of Neuropsychopharmacology at Imperial College London.
Value-added medicines: the AUD franchise
Differentiated ketamine- and esketamine-based treatments built on established pharmacology, clinical experience and regulatory precedent.
Value creation | Nearer-term clinical and regulatory catalysts
De novo drug development: the engine
Creating proprietary new chemical entities (NCEs) with composition-of-matter filings in high-burden addiction and psychiatric disorders.
Value creation | Longer-duration IP and early-stage upside
The SVN-001 Phase 3 is co-funded by the National Institute for Health and Care Research (NIHR), the Medical Research Council (MRC) and Solvonis, and sponsored by the University of Exeter. The U.S. National Institute on Drug Abuse (NIDA) funds the SVN-015 evaluation, which has advanced into further NIDA-funded studies.
Leadership combines psychedelic science, public-company execution and commercial experience
Public-company leadership; biopharma capital markets, M&A and psychedelics strategy.
Edmond J Safra Professor of Neuropsychopharmacology, Imperial College London; former Chair, UK Advisory Council on the Misuse of Drugs.
Public-company finance, governance and capital-markets execution.
Experience across addiction, psychiatry and neurology; biopharma capital markets and M&A; drug development and commercialisation
Solvonis: towards freedom
The name Solvonis comes from the Latin root solv-, meaning to release, unbind and free, with a suffix meaning unity.
It reflects what we are working towards: new, effective treatments that free people from debilitating mental health conditions, relieve suffering, and help them reconnect with their families and communities.